# Compare Epitalon and NAD+ — Highlander Peptide

> A side-by-side comparison of Epitalon and NAD+ — two Longevity & Cellular Health research compounds — across peptide class, evidence base, administration studied, regulatory status and key cautions.

Where Epitalon and NAD+ converge on the aging question, where they diverge in evidence quality, and how far the research behind each one actually reaches.

## The short version

This page lines up [Epitalon](/epitalon) and [NAD+](/nad) on the dimensions that matter when reading longevity research: what kind of molecule each one is, where it has been most studied, how strong that evidence is, how it was administered in studies, its regulatory standing, and its single most important caution. The headline is straightforward but worth stating precisely. Both are studied in the context of aging biology. NAD+ has the more robust human trial base — multiple RCTs confirming blood NAD+ elevation, and one demonstrating a metabolic endpoint in prediabetic women [10] — but its clinical translation to longevity outcomes in healthy adults is explicitly described as limited by the most current review [8]. Epitalon has a longer preclinical record and more evocative claims (telomerase induction, lifespan extension in mice), but its human evidence is observational, uncontrolled, and used a different compound [5]. Neither is a treatment for any aging-related condition; neither is presented here with a human dose.

## The comparison matrix

| Dimension | Epitalon | NAD+ |
| --- | --- | --- |
| Compound class | Synthetic pineal tetrapeptide (4 aa, Ala-Glu-Asp-Gly) | Endogenous redox coenzyme / dietary supplement / IV wellness compound |
| Most-studied in | Telomere maintenance; pineal melatonin synthesis; mouse lifespan models | Cellular energy metabolism; sirtuin and DNA-repair signaling; age-related metabolic function |
| Evidence base (model) | In vitro human cells [4][2]; rat pinealocyte culture [3]; mouse lifespan [6]; human observational (epithalamin) [5] | Human RCTs on blood NAD+ elevation [9][12]; one human metabolic endpoint RCT [10]; foundational multi-species review [11] |
| Administration studied | Subcutaneous (mice); in vitro (cell culture) [4][6] | Oral NMN / NR in humans [9][10][12]; IV infusion (wellness context) [8] |
| Regulatory status | Not approved for any human indication; classified as research chemical (US, EU, UK) | Oral precursors marketed as dietary supplements (NR established; NMN status contested by FDA); IV compounded; not an approved drug |
| Key caution | Single-lineage evidence origin; observational human data uses different compound; unresolved telomerase-cancer duality [1][2] | Blood NAD+ elevation is reliable; translation to clinical aging endpoints in healthy adults remains unestablished [8] |

## Compound class

The two compounds are fundamentally different in kind. Epitalon is a synthetic tetrapeptide — four amino acids — derived from the composition of a bovine pineal extract, and it is a research chemical with no approved human use [1]. NAD+ is an endogenous molecule present in every cell of the body; it is not a research-only compound but a dietary supplement and wellness-IV ingredient subject to its own regulatory complexities [8]. That difference in origin shapes their evidence bases: Epitalon has been studied mostly in preclinical settings by a discrete research program, while NAD+ precursors have been through multiple independent, multi-center human RCTs.

## Most-studied in

Each compound has a mechanistic home territory. Epitalon's research centers on two axes: telomere maintenance (hTERT upregulation and telomere elongation in human cell lines [4][2]) and the pineal melatonin synthesis pathway (AANAT and pCREB stimulation in rat pinealocytes [3]). NAD+ is studied as the substrate of aging-relevant enzymes — sirtuins, PARPs, CD38 — across the full range of age-related biology, but the human trial work has concentrated on metabolic outcomes: blood NAD+ levels, insulin sensitivity, and physical performance [9][10][12].

## Evidence base (model)

This is where the two genuinely separate, and where the picture is more nuanced than a simple stronger-weaker ranking. NAD+ precursor supplementation has more human RCT evidence: blood NAD+ elevation is robust, dose-dependent, and replicated across independent groups [9][12]. The 2021 Science NMN trial produced a controlled metabolic endpoint — improved muscle insulin sensitivity in prediabetic women [10]. But a 2025 Nature Metabolism review explicitly characterized translation to clinical aging endpoints as limited and tissue NAD+ data as sparse [8]. Epitalon's cell-level telomere claims have now been replicated by an independent group [2], which is a meaningful advance; but the human evidence remains a single observational cohort that used a different compound (epithalamin extract, not synthetic Epitalon), without randomization or placebo [5].

## Administration studied

Routes track the research context. Epitalon has been given subcutaneously in mouse lifespan studies and added directly to cell culture in vitro [6][4]; there is no human pharmacokinetic study of the compound in any form — the often-cited short half-life is an inference, not a measured value [1]. NAD+ precursors have been studied as oral capsules in multiple human RCTs [9][10][12]; IV infusion of compounded NAD+ is a separate wellness-market practice with minimal controlled trial backing and a specific safety concern (a Class I FDA recall for bacterial endotoxin in one compounded batch) [8].

## Regulatory / status

Epitalon has no approved indication anywhere in major Western markets; it is a research chemical not cleared by FDA, EMA, or MHRA [1]. WADA does not specifically list it by name as of the 2025 review, but peptide classifications are revised periodically and current status should be verified independently. NAD+ itself and its precursors are sold as dietary supplements, though NMN faces an FDA challenge to that classification; compounded injectable NAD+ is not an approved drug and has been subject to a Class I recall [8]. The regulatory profiles are therefore different in kind — Epitalon is a research-only compound, while NAD+ precursors occupy a complex middle ground between supplement and contested-drug status.

## Key caution

Each compound carries a defining caveat that distinguishes it from the marketing narrative. For Epitalon: most of its foundational evidence originates from one research lineage; the human mortality data used a different compound without a placebo arm; and the mechanism the headline claims rest on — telomerase reactivation — is precisely the same pathway that is a hallmark of most cancers, with the 2025 cell study finding ALT activation in cancer lines specifically [2][1]. For NAD+: blood NAD+ elevation is real and reproducible, but the 2025 Nature Metabolism review — the most current authoritative synthesis — concluded that the clinical translation to longevity endpoints in humans remains limited, and that much of the compelling anti-aging data is still in rodents [8]. Reading them together, the message is consistent with the broader longevity-research field: the mechanisms are plausible, the preclinical signals are real, and the controlled human evidence for the headline claim — genuine aging protection — is not yet there for either.

---

A peer-reviewed literature digest for longevity and cellular health research — citations held to source, claims held to species.